Expert faculty explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.
Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis
CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis
Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.
Hear CCO faculty Rita Basu, MD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.